{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T16:35:40Z","timestamp":1760978140845,"version":"3.40.4"},"reference-count":2,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ORL"],"published-print":{"date-parts":[[2000]]},"abstract":"<jats:p>Intratympanic and systemic dexamethasone treatment of M\u00e9ni\u00e8re\u2019s disease (MD) was evaluated in a prospective study. Seventeen patients (6 men and 11 women) with MD (5 right-sided, 11 left-sided and 1 bilateral) were treated with three 0.2- to 0.4-ml injections of intratympanic dexamethasone hyaluronate (16\u00a0mg\/ml) during a week and with an initial intramuscular dexamethasone injection of 15\u00a0mg. Most of patients were in stage 3, and the mean duration of MD was 5.3 years. Pure-tone and speech audiometry and the symptom scale of the patients were followed up for 1 year after the treatment. Symptoms of aural fullness, hearing loss, tinnitus and vertigo did not improve significantly. However, sufficient control of vertigo was achieved in 76% of the patients. In conclusion, no definite treatment effect has yet been shown for intratympanic and systemic dexamethasone treatment. Therefore, the clinical use of dexamethasone in MD needs further investigation.<\/jats:p>","DOI":"10.1159\/000027730","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T09:24:25Z","timestamp":1050398665000},"page":"117-120","source":"Crossref","is-referenced-by-count":28,"title":["Intratympanic and Systemic Dexamethasone for M\u00e9ni\u00e8re\u2019s Disease"],"prefix":"10.1159","volume":"62","author":[{"given":"T.P.","family":"Hirvonen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Peltomaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ylikoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2000,5,5]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5955(94)90269-0"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1080\/00016489850182413"}],"container-title":["ORL"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/27730","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/27730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:09:44Z","timestamp":1745467784000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000027730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000]]},"references-count":2,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2000,6,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000027730","archive":["Portico"],"relation":{},"ISSN":["0301-1569","1423-0275"],"issn-type":[{"type":"print","value":"0301-1569"},{"type":"electronic","value":"1423-0275"}],"subject":[],"published":{"date-parts":[[2000]]}}}